Rush University Cancer Center | Strategic Alliance Partners

March 20, 2018

Ruta D. Rao, MD, associate professor, Rush University Medical Center, discusses the results of the SOFT trial, presented at the 2017 San Antonio Breast Cancers Symposium.

November 02, 2017

Mary Jo Fidler, MD, discusses targeting the EGFR-gene activating mutations, first- and second-generation inhibitors, and the potential of osimertinib.

October 07, 2017

Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses PD-L1 as a biomarker in non-small cell lung cancer.

October 03, 2017

Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses liquid biopsies in lung cancer.

September 28, 2017

Mary Jo Fidler, MD, associate professor, medical oncology, hematology, internal medicine, Rush University Medical Center, discusses osimertinib (Tagrisso) in patients with EGFR T790M-positive non–small cell lung cancer.

July 19, 2017

As clinicians have gained an improved understanding of the biology of soft-tissue sarcoma malignancies, the ability to better distinguish and identify subtypes has extended the hope of targeted treatment options.

April 29, 2017

Mary Jo Fidler, MD, discusses aiming to improve platinum-based doublet therapy in NSCLC, as well as the role of chemotherapy for non-driver adenocarcinoma in the future.

October 26, 2016

Mary Jo Fidler, MD, associate professor, medical oncology, hematology, internal medicine, Rush University Medical Center, discusses how early and persistent oligoclonal T cell expansion correlates with durable response to anti-PD1 therapy in non-small cell lung cancer treatment (NSCLC).

November 12, 2014

The Centers for Medicare & Medicaid Services (CMS) announced that the agency plans to cover lung cancer screening using low-dose computed tomography (LDCT) for certain former and current smokers, a decision that could affect an estimated 4 million people.

March 17, 2014

The oncolytic immunotherapeutic vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage in 64% of patients with advanced melanoma, including a marked reduction in the size of uninjected metastatic lesions

August 14, 2013

Any lingering skepticism about immunotherapy as an anticancer strategy appears to have been banished by research presented at the 2013 ASCO Annual Meeting.